Today, Adeona Pharmaceuticals, Inc., a developer of innovative medicines used in the treatment of serious central nervous system diseases, announced that it has executed an agreement with TG United, Inc. of Brooksville, FL, to provide commercial-scale manufacturing capabilities for reaZin. reaZin is Adeona’s product candidate for the dietary management of Alzheimer’s disease and mild cognitive impairment, as a prescription medical food. The company is currently focusing on further developing this product.
Results from Adeona’s clinical study evaluating reaZin were presented last week at the 63rd Annual Meeting of the American Academy of Neurology. The primary outcome of increasing serum zinc and decreasing serum free copper was effectively demonstrated in patients treated with the substance. Additionally, the average cognitive function of the placebo group declined over 6 months, while trends favoring the cognitive function of patients administered reaZin were observed in all three standardized cognitive tests. The results suggest that reaZin may provide an important dietary benefit to Alzheimer’s disease patients.
“Executing this agreement for the manufacturing of our product candidate, reaZin, is an important step for commercialization,” stated James S. Kuo, M.D., M.B.A., Adeona’s Chief Executive Officer. “With the recent news that revised guidelines for diagnosing Alzheimer’s disease could double the population size, we are excited that reaZin may be of benefit to this growing population, particularly in the earlier stages.”
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.